Abstract
Human ovarian tumors (derived from A2780 cells), growing as subcutaneous xenografts in immunodeficient mice, develop melphalan-resistant cells after a single treatment of the tumor-bearing animal with the drug [Caffrey, Zhang and Frenkel, submitted for publication]. Treatment of the animals with selenite by i.p. injection prevented the development of primary resistance to melphalan as well as cross-resistance to cisplatin. Selenite treatment also prevented the melphalan-induced increase in the cellular level of glutathione. In contrast, selenite administered s.c. or in drinking water had relatively little effect on the development of resistance. The results in this animal model suggest that selenite may be clinically useful in preventing the development of drug resistance during chemotherapy of cancer.
| Original language | American English |
|---|---|
| Pages (from-to) | 3017-3020 |
| Number of pages | 4 |
| Journal | Anticancer Research |
| Volume | 18 |
| Issue number | 4 C |
| State | Published - Jul 1998 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Keywords
- Drug resistance
- Glutathione
- Melphalan
- Ovarian tumors
- Selenite
Fingerprint
Dive into the research topics of 'Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver